Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.
Name | Title | Since | Age |
|---|---|---|---|
| Takayuki Kusanagi | Chairman of the Board of Directors, President & CEO | 2020 | 68 |
| Yoshiki Sawa | Chief Medical Science Officer & Director | 2026 | 71 |
| Tadayuki Tanimura | Executive VP & Director | 2024 | 45 |
| Kazuyoshi Hirao | Executive VP, Chief Business Officer & Director | 2025 | 64 |
| Kenichiro Yoshida | Independent Outside Director | 2023 | 63 |
| Yukihiro Kato | Independent Outside Director | 2026 | - |
| Kotaro Yamamoto | Outside Audit & Supervisory Board Member | 2020 | 71 |
| Shinji Abe | External Audit & Supervisory Board Member | 2020 | 47 |
| Norihiro Ashida | Outside Audit & Supervisory Board Member | 2024 | 72 |